US2010196381A1PendingUtilityA1

P. ariasi polypeptides, p. perniciosus polypeptides and methods of use

39
Assignee: US GOV HEALTH & HUMAN SERVPriority: Sep 19, 2002Filed: Apr 13, 2010Published: Aug 5, 2010
Est. expirySep 19, 2022(expired)· nominal 20-yr term from priority
Inventors:Jesus G. ValenzuelaJose M. C. RibieroShaden KamhawiYasmine BelkaidLaurent FischerJean-Christophe AudonnetFrancis Milward
A61P 33/02A61P 37/04A61K 38/00A61K 39/0003A61K 39/008A61K 2039/53C07K 14/43577Y02A50/30
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Substantially purified salivary P. ariasi and P. perniciosus polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the P. ariasi and P. perniciosus polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating or preventing Leishmaniasis are disclosed.

Claims

exact text as granted — not AI-modified
1 . A substantially purified salivary  P. ariasi  polypeptide, wherein the polypeptide comprises:
 a) residues 21-65 of the amino acid sequence set forth as SEQ ID NO:39;   b) an amino acid sequence at least 90% identical to residues 21-65 of SEQ ID NO: 39; or   c) an immunogenic fragment comprising at least fifteen consecutive amino acids of residues 21-65 of SEQ ID NO: 39,   
       and wherein administration of the polypeptide to a subject produces an immune response to  P. ariasi.    
     
     
         2 . The substantially purified salivary  P. ariasi  polypeptide of  claim 1 , wherein the polypeptide comprises:
 a) residues 21-65 of the amino acid sequence set forth as SEQ ID NO:39;   b) an amino acid sequence at least 90% identical to residues 21-65 of SEQ ID NO: 39;   c) a conservative variant of residues 21-65 of SEQ ID NO:39; or   d) an immunogenic fragment comprising at least fifteen consecutive amino acids of residues 21-65 of SEQ ID NO: 39,   
       and wherein administration of the polypeptide to a subject produces an immune response to  P. ariasi.    
     
     
         3 . The  P. ariasi  polypeptide of  claim 1 , wherein the polypeptide comprises residues 21-65 of SEQ ID NO: 39, or a conservative variant thereof. 
     
     
         4 . The  P. ariasi  polypeptide of  claim 3 , wherein the polypeptide comprises residues 21-65 of SEQ ID NO: 39. 
     
     
         5 . An immunogenic fragment of the polypeptide of  claim 4 , wherein the immunogenic fragment comprises at least fifteen contiguous amino acids of residues 21-65 of SEQ ID NO: 39. 
     
     
         6 . The  P. ariasi  polypeptide of  claim 1 , wherein the polypeptide comprises an amino acid sequence at least 90% identical to residues 21-65 of SEQ ID NO: 39. 
     
     
         7 . The  P. ariasi  polypeptide of  claim 6 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to residues 21-65 of SEQ ID NO: 39. 
     
     
         8 . The  P. ariasi  polypeptide of  claim 7 , wherein the polypeptide comprises an amino acid sequence at least 98% identical to residues 21-65 of SEQ ID NO: 39. 
     
     
         9 . The  P. ariasi  polypeptide of  claim 8 , wherein the polypeptide comprises residues 21-65 of the amino acid sequence set forth as SEQ ID NO: 39. 
     
     
         10 . The  P. ariasi  polypeptide of  claim 9 , wherein the polypeptide consists of residues 21-65 of the amino acid sequence set forth as SEQ ID NO: 39. 
     
     
         11 . An isolated nucleic acid encoding the  P. ariasi  polypeptide of  claim 1 . 
     
     
         12 . The nucleic acid of  claim 11 , wherein the nucleic acid comprises a sequence as set forth as residues 86-220 SEQ ID NO: 40, or a degenerate variant thereof. 
     
     
         13 . The nucleic acid of  claim 11 , wherein the nucleic acid comprises a sequence as set forth as residues 86-220 of SEQ ID NO: 40. 
     
     
         14 . The nucleic acid of  claim 11 , wherein the nucleic acid encodes an amino acid sequence at least 90% identical to the amino acid sequence set forth as residues 21-65 of SEQ ID NO: 39. 
     
     
         15 . The nucleic acid of  claim 14 , wherein the nucleic acid encodes an amino acid sequence at least 95% identical to the amino acid sequence set forth as residues 21-65 of SEQ ID NO: 39. 
     
     
         16 . The nucleic acid of  claim 15 , wherein the nucleic acid encodes an amino acid sequence at least 98% identical to the amino acid sequence set forth as residues 21-65 of SEQ ID NO: 39. 
     
     
         17 . The nucleic acid of  claim 11 , operably linked to an expression control sequence. 
     
     
         18 . The nucleic acid of  claim 17 , wherein the expression control sequence comprises a promoter. 
     
     
         19 . The nucleic acid of  claim 18 , wherein the promoter comprises an inducible or constitutive promoter. 
     
     
         20 . The nucleic acid of  claim 19 , wherein the promoter comprises a cytomegalovirus promoter. 
     
     
         21 . A vector comprising the nucleic acid of  claim 11 . 
     
     
         22 . The vector of  claim 21 , wherein the vector comprises a plasmid. 
     
     
         23 . The vector of  claim 21 , wherein the vector comprises a viral vector. 
     
     
         24 . A host cell transformed with the vector of  claim 21 . 
     
     
         25 . An antibody that specifically binds the polypeptide of  claim 1 . 
     
     
         26 . The antibody of  claim 25 , wherein the antibody comprises a monoclonal antibody. 
     
     
         27 . The antibody of  claim 25 , comprising a detectable label. 
     
     
         28 . The antibody of  claim 27 , wherein the label comprises a fluorescent, enzymatic or radioactive label. 
     
     
         29 . A pharmaceutical composition comprising a therapeutically effective amount of the  P. ariasi  polypeptide of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         30 . A pharmaceutical composition comprising a therapeutically effective amount of the nucleic acid of  claim 11  and a pharmaceutically acceptable carrier. 
     
     
         31 . A method for inducing an immune response to a  P. ariasi  polypeptide in a subject, comprising
 administering to the subject a therapeutically effective amount of the  P. ariasi  polypeptide of  claim 1 , or a therapeutically effective amount of a polynucleotide encoding the  P. ariasi  polypeptide of  claim 1 , thereby inducing the immune response.   
     
     
         32 . The method of  claim 31 , wherein the immune response comprises a T cell response. 
     
     
         33 . The method of  claim 31 , wherein the immune response comprises a B cell response. 
     
     
         34 . The method of  claim 32 , wherein the subject is a non-human veterinary subject. 
     
     
         35 . The method of  claim 34 , wherein the subject is a dog. 
     
     
         36 . The method of  claim 31 , wherein the subject is a human. 
     
     
         37 . A method for inhibiting a symptom of a Leishmania infection or preventing a Leishmania infection in a subject, comprising administering to the subject a therapeutically effective amount of the  P. ariasi  polypeptide of  claim 1 , or a therapeutically effective amount of a polynucleotide encoding the  P. ariasi  polypeptide of  claim 1 , thereby inhibiting the symptom of the Leishmania infection or preventing the Leishmania infection. 
     
     
         38 . The method of  claim 37 , wherein the subject is a non-human veterinary subject. 
     
     
         39 . The method of  claim 38 , wherein the subject is a dog. 
     
     
         40 . The method of  claim 37 , wherein the subject is a human.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.